-transparent.png){kind=logo}
Twenty-two healthy infants and children received either cold-recombinant, trivalent influenza vaccine or placebo in a three-dose vaccine trial. Most (82%) who received vaccine were seronegative to all three vaccine strains (10(6) TCID50/dose each): A/Kawasaki/9/86 (H1N1), A/Los Angeles/2/87 (H3N2), and B/Yamagata/16/88. Vaccine was administered intranasally at time 0 and 2 and 4 months later. The vaccine was well tolerated and immunogenic when administered in a multidose regimen. The first dose stimulated antibody to H1, H3, and B in 59%, 94%, and 35% of vaccinees, respectively, by hemagglutination inhibition (HAI) or ELISA. After two doses of vaccine, 93%, 93%, and 80% had antibody by HAI or ELISA to H1, H3, and B, respectively. Most vaccinees (67%) responded to all three viruses after two doses of vaccine. The third dose contributed little to the vaccine's immunogenicity. Multidose trivalent influenza vaccine is safe and induces an immune response in most vaccinees after two doses.
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
November 2003,
Immunology and allergy clinics of North America,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
February 2007,
The New England journal of medicine,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
July 2007,
The Pediatric infectious disease journal,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
December 2001,
Philosophical transactions of the Royal Society of London. Series B, Biological sciences,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
July 1993,
The Journal of infectious diseases,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
April 2004,
Expert review of vaccines,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
November 2007,
Vaccine,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
October 2006,
The Pediatric infectious disease journal,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
August 1999,
Vaccine,
E M Swierkosz, and
F K Newman, and
E L Anderson, and
S L Nugent, and
G B Mills, and
R B Belshe
July 1993,
The Pediatric infectious disease journal,
